Dr. Alejandro Luque Hernández

Non-invasive neurostimulation is a set of techniques that modulate brain activity by applying magnetic fields or low-intensity electrical currents over the scalp. Over the past 20 years it has moved from being an experimental tool to an intervention with scientific support across a range of neurological and psychiatric conditions.

This article covers:

  • An overview of neuromodulation
  • The neurobiological basis: neuroplasticity
  • A closer look at repetitive transcranial magnetic stimulation (rTMS)
  • A closer look at transcranial direct current stimulation (tDCS)

What is neuromodulation?

Neuromodulation means the controlled alteration of neuronal activity through physical or electrical stimuli. With non-invasive techniques, the aim is not to stimulate for its own sake but to induce functional change in neural networks that are not working well.

The point is not to create artificial activity but to make it easier for brain circuits to reorganize, in conditions such as:

  • Treatment-resistant depression
  • Anxiety disorders
  • Chronic pain
  • Central sensitivity syndromes
  • Cognitive sequelae
  • Functional neurological disorders

These techniques act on networks, not on isolated symptoms.

Neuroplasticity: the biological basis

The scientific foundation of neurostimulation is neuroplasticity: the capacity of the nervous system to change its structure and function in response to experience, learning or injury. This happens through:

  • Long-term potentiation (LTP)
  • Long-term depression (LTD)
  • Modulation of synapses
  • Changes in functional connectivity
  • Reorganization of cortical networks

Techniques such as rTMS and tDCS induce changes in cortical excitability that can favor LTP-like or LTD-like processes, depending on the protocol used (Pascual-Leone et al., 1998; Nitsche & Paulus, 2000).

Put simply: they do not cure anything directly. They create neurobiological conditions that make functional reorganization easier.

That is why they are usually combined with psychotherapy or cognitive rehabilitation. The stimulation prepares the ground; the therapeutic work consolidates the change.

rTMS: repetitive transcranial magnetic stimulation

rTMS uses pulsed magnetic fields to induce electrical currents in the cerebral cortex. These pulses can modulate neuronal excitability depending on their frequency:

  • High frequency (above 5 Hz): a facilitating effect
  • Low frequency (1 Hz or below): an inhibitory effect

Clinical evidence

rTMS has regulatory approval in several countries for major depression that has not responded to medication (O'Reardon et al., 2007; George et al., 2010).

There is also growing evidence in:

  • Obsessive-compulsive disorder
  • Neuropathic pain
  • Migraine
  • Rehabilitation after stroke
  • Functional motor disorders

Neuroimaging studies show that rTMS does not act only at the point stimulated. It modulates distributed networks, particularly fronto-limbic circuits in depression.

Safety

rTMS is considered safe when international guidelines are followed. The most significant adverse effect, and a rare one, is a seizure, with a very low incidence under appropriate protocols (Rossi et al., 2009; 2021).

tDCS: transcranial direct current stimulation

tDCS applies a continuous, low-intensity electrical current, usually 1 to 2 mA, through electrodes placed on the scalp.

Unlike rTMS, it does not induce action potentials directly. It modulates neuronal excitability:

  • The anode increases excitability
  • The cathode decreases it

Clinical evidence

The evidence for tDCS is solid in research and growing in clinical application, particularly in:

  • Mild to moderate depression
  • Cognitive rehabilitation
  • Chronic pain
  • Fatigue
  • Motor disorders

Effect sizes tend to be smaller than those of rTMS in treatment-resistant depression, but tDCS has advantages: it is portable, inexpensive and has an excellent safety profile (Nitsche et al., 2008; Brunoni et al., 2016).

Individual protocols: designed around each person's needs

One of the fundamental principles of clinical neuromodulation is that there is no universal protocol valid for every patient.

Standardized schemes supported by clinical trials do exist, for instance stimulation of the left DLPFC in major depression. But responsible application requires individualization based on:

  • An accurate diagnosis
  • The predominant symptom profile
  • Medical and psychiatric comorbidity
  • The functional pattern, whether affective, cognitive or somatic
  • Previous response to treatment
  • Individual tolerance

The choice of cortical target, the frequency, the intensity, the number of sessions and the combination with other interventions all have to follow a neurobiological and clinical logic, not simply a protocol.

In contemporary models, neuromodulation forms part of a multimodal approach in which stimulation facilitates plasticity and psychotherapeutic or rehabilitation work consolidates the change.

Personalization does not mean improvising. It means adapting the evidence to the clinical particularity of each person.

Uses in central sensitivity and functional neurological disorders

Interest has grown in recent years in using rTMS and tDCS in conditions associated with disturbances of functional networks rather than with visible structural lesions. These include:

  • Central sensitization syndrome
  • Fibromyalgia
  • Persistent fatigue
  • Chronic non-structural pain
  • Functional neurological disorders, both motor and sensory

In these conditions, studies suggest altered connectivity between the prefrontal cortex, the limbic system, the somatosensory cortex and motor control networks.

Neuromodulation may help to:

  • Regulate cortical hyperexcitability
  • Modulate pain processing circuits
  • Reorganize dysfunctional motor networks
  • Support integration with rehabilitation and psychotherapy

The evidence is still mixed and continues to develop, but preliminary results support its use as part of structured, integrative models rather than as an isolated intervention.

Responsible clinical integration

One point matters above all: neurostimulation does not replace a full clinical assessment.

Its effectiveness depends on:

  • An appropriate diagnosis
  • Correct selection of the cortical target
  • Evidence-based protocols
  • Integration with psychotherapy or rehabilitation
  • Structured clinical follow-up

Neuromodulation is not a standalone intervention. It is part of a model of care built on functional networks and brain plasticity.

Conclusion

rTMS and tDCS are modern tools with a solid neurobiological basis and growing scientific support. Their value does not lie in the technology itself but in how it is integrated into structured clinical models.

The evidence shows they can induce real functional change in the brain networks involved in complex disorders. Applying them, however, demands clinical judgment, clear protocols and measurement of outcomes.

Technology without a clinical framework is noise. Technology integrated into a structured model is evidence-based medicine.

References

Brunoni, A. R., et al. (2016). Trial of electrical direct-current therapy versus escitalopram for depression. New England Journal of Medicine, 376(26), 2523–2533.

George, M. S., et al. (2010). Daily left prefrontal TMS therapy for major depressive disorder. Archives of General Psychiatry, 67(5), 507–516.

Nitsche, M. A., & Paulus, W. (2000). Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. Journal of Physiology, 527(3), 633–639.

Nitsche, M. A., et al. (2008). Transcranial direct current stimulation: State of the art 2008. Brain Stimulation, 1(3), 206–223.

O'Reardon, J. P., et al. (2007). Efficacy and safety of transcranial magnetic stimulation in major depression. Biological Psychiatry, 62(11), 1208–1216.

Pascual-Leone, A., et al. (1998). Transcranial magnetic stimulation and neuroplasticity. Philosophical Transactions of the Royal Society B, 354(1387), 1229–1238.

Rossi, S., et al. (2009). Safety, ethical considerations, and application guidelines for TMS. Clinical Neurophysiology, 120(12), 2008–2039.

Rossi, S., et al. (2021). Safety and recommendations for TMS: Updated guidelines. Clinical Neurophysiology, 132(1), 269–306.